Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules

BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12–23 months, with a booster dose 12–24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres i...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Sadarangani, M, Sell, T, Iro, M, Snape, M, Voysey, M, Finn, A, Heath, P, Bona, G, Esposito, S, Diez-Domingo, J, Prymula, R, Odueyungbo, A, Toneatto, D, Pollard, A
Format:	Journal article
Veröffentlicht:	Canadian Medical Association 2017

Ähnliche Einträge

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
von: Iro, M, et al.
Veröffentlicht: (2017)

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
von: Iro, M, et al.
Veröffentlicht: (2016)

Four component meningococcal capsular Group B vaccine in preterm infants.
von: Sadarangani, M, et al.
Veröffentlicht: (2017)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
von: Pace, D, et al.
Veröffentlicht: (2016)

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.
von: Gossger, N, et al.
Veröffentlicht: (2012)

The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.
von: Rollier, C, et al.
Veröffentlicht: (2014)

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age
von: Snape, M, et al.
Veröffentlicht: (2015)

Serogroup B meningococcal vaccines-an unfinished story.
von: Sadarangani, M, et al.
Veröffentlicht: (2010)

Differences in immunization site pain in toddlers vaccinated with either the 10- or the 13-valent pneumococcal conjugate vaccine
von: Trück, J, et al.
Veröffentlicht: (2018)

Meningococcal polysaccharide-protein conjugate vaccines.
von: Snape, MD, et al.
Veröffentlicht: (2005)

Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
von: Pollard, A, et al.
Veröffentlicht: (2013)

Meningococcal B Vaccination (4CMenB) in Infants and Toddlers
von: Susanna Esposito, et al.
Veröffentlicht: (2015-01-01)

Meningococcal vaccine. From capsular polysaccharides of microbes to proteases
von: A P Alliluyev, et al.
Veröffentlicht: (2012-12-01)

Challenges and progress in the development of a serogroup B meningococcal vaccine.
von: Lewis, S, et al.
Veröffentlicht: (2009)

Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.
von: McQuaid, F, et al.
Veröffentlicht: (2014)

Meningococcal vaccines.
von: Rüggeberg, J, et al.
Veröffentlicht: (2004)

Meningococcal vaccines.
von: Collins, C, et al.
Veröffentlicht: (2002)

Meningococcal vaccines.
von: Bethell, D, et al.
Veröffentlicht: (2002)

Meningococcal vaccination in pregnancy
von: Bahaa Abu Raya, et al.
Veröffentlicht: (2018-05-01)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
von: Snape, M, et al.
Veröffentlicht: (2013)

Meningococcal polysaccharide-protein conjugate vaccines (vol 5, pg 21, 2005)
von: Snape, MD, et al.
Veröffentlicht: (2005)

Vaccines for prevention of meningococcal disease.
von: Pollard, A, et al.
Veröffentlicht: (2000)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
von: Read, R, et al.
Veröffentlicht: (2014)

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial
von: Read, R, et al.
Veröffentlicht: (2014)

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
von: Trück, J, et al.
Veröffentlicht: (2016)

Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function
von: Martinón-Torres, FL, et al.
Veröffentlicht: (2018)

Prevalence and decay of maternal pneumococcal and meningococcal antibodies: a meta-analysis of type-specific decay rates
von: Voysey, M, et al.
Veröffentlicht: (2017)

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.
von: Snape, MD, et al.
Veröffentlicht: (2013)

An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
von: Dold, C, et al.
Veröffentlicht: (2023)

Meningococcal vaccine evolution
von: Gianni Bona, et al.
Veröffentlicht: (2012-06-01)

Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.
von: Jeppesen, C, et al.
Veröffentlicht: (2015)

Erratum: Meningococcal polysaccharide-protein conjugate vaccines (Lancet Infective Diseases (2005) 5 (21-30)
von: Snape, MD, et al.
Veröffentlicht: (2005)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
von: Snape, MD, et al.
Veröffentlicht: (2009)

Emerging clinical experience with vaccines against group B meningococcal disease
von: Wilkins, A, et al.
Veröffentlicht: (2017)

Emerging experience with meningococcal serogroup B protein vaccines
von: Daniela Toneatto, et al.
Veröffentlicht: (2017-05-01)

Quadrivalent meningococcal conjugate vaccines
von: Pace, D, et al.
Veröffentlicht: (2009)

Quadrivalent meningococcal conjugate vaccines.
von: Pace, D, et al.
Veröffentlicht: (2009)

Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component.
von: Sheerin, D, et al.
Veröffentlicht: (2019)

The epidemiology of meningococcal disease and the impact of vaccines.
von: Khatami, A, et al.
Veröffentlicht: (2010)

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply
von: Snape, MD, et al.
Veröffentlicht: (2006)